Patents by Inventor Seung-Yub Shin

Seung-Yub Shin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240262819
    Abstract: Provided are a compound having an inhibitory activity against glucosylceramide synthase (GCS), i.e., compounds having a 2,3-dihydro-1H-indene, 1,2,3,4-tetrahydronaphthalene, or chromane moiety, or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof, wherein the compound or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and exhibits the effects of alleviating symptoms in the central nervous system as well as in the peripheral nervous system, through excellent blood-brain barrier permeability, and therefore, the compound or pharmaceutically acceptable salt thereof can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
    Type: Application
    Filed: May 10, 2022
    Publication date: August 8, 2024
    Applicants: YUHAN CORPORATION, GREEN CROSS CORPORATION
    Inventors: Dong-Hoon KIM, Jae-Eun JOO, Seung-Yub SHIN, Sool-Ki KWON, Jong-Suk PARK
  • Publication number: 20230002380
    Abstract: Provided are a compound having a chromane, isochromane, thiochromane, or tetrahydroquinoline moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof, wherein the compound having a chromane, isochromane, thiochromane, or tetrahydroquinoline moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
    Type: Application
    Filed: November 12, 2020
    Publication date: January 5, 2023
    Applicants: YUHAN CORPORATION, GREEN CROSS CORPORATION
    Inventors: Dong-Hoon KIM, Jae-Eun JOO, Eui-Chul LEE, Tae-Dong HAN, Seung-Yub SHIN, Sool-Ki KWON
  • Publication number: 20230002379
    Abstract: Provided are a compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same and a use thereof, where the compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
    Type: Application
    Filed: November 12, 2020
    Publication date: January 5, 2023
    Applicants: YUHAN CORPORATION, GREEN CROSS CORPORATION
    Inventors: Dong-Hoon KIM, Jae-Eun JOO, Eui-Chul LEE, Tae-Dong HAN, Seung-Yub SHIN, Sool-Ki KWON, Ji-Hye KIM
  • Publication number: 20220402909
    Abstract: Provided are a compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same and a use thereof, where the compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
    Type: Application
    Filed: November 12, 2020
    Publication date: December 22, 2022
    Applicants: YUHAN CORPORATION, GREEN CROSS CORPORATION
    Inventors: Dong-Hoon KIM, Jae-Eun JOO, Eui-Chul LEE, Tae-Dong HAN, Seung-Yub SHIN, Sool-Ki KWON, Young-Gyu KONG, Sang-Ho MA, Ick-Hwan SON
  • Patent number: 11046742
    Abstract: Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3? or CCL3? is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3? or CCL3? in the CCL3 variant.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: June 29, 2021
    Assignee: YUHAN CORPORATION
    Inventors: Su Youn Nam, Jong Gyun Kim, Byung Hyun Choi, June Hyung Lee, Ju Young Park, Jun Kyung Lee, Na Rae Lee, Ki Hong Kim, Seul Gi Kim, Se Woong Oh, Seung Yub Shin, Ho Woong Kang, Su Jin Ahn, Soo Yong Chung
  • Publication number: 20190153055
    Abstract: Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3? or CCL3? is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3? or CCL3? in the CCL3 variant.
    Type: Application
    Filed: April 19, 2017
    Publication date: May 23, 2019
    Inventors: Su Youn Nam, Jong Gyun Kim, Byung Hyun Choi, June Hyung Lee, Ju Young Park, Jun Kyung Lee, Na Rae Lee, Ki Hong Kim, Seul Gi Kim, Se Woong Oh, Seung Yub Shin, Ho Woong Kang, Su Jin Ahn, Soo Yong Chung
  • Patent number: 9376420
    Abstract: The present invention provides a 4,5-dihydro-1H-pyrazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The 4,5-dihydro-1H-pyrazole derivative or its pharmaceutically acceptable salt effectively increases the LXR transcriptional activity, and therefore can be usefully applied for preventing or treating a dysfunction in cholesterol metabolism, such as cholesterol gallstone, hyperlipidemia, or coronary atherosclerosis.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: June 28, 2016
    Assignee: YUHAN CORPORATION
    Inventors: Chan-Sun Park, Young-Hwan Kim, Gyu-Jin Lee, Youn Hur, Eun-Hye Jung, Hee-Jae Tak, Seung-Yub Shin, Ho-Jin Lee, Chun-Ho Lee, Koo-Yeon Lee
  • Publication number: 20150291563
    Abstract: The present invention provides a 4,5-dihydro-1H-pyrazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The 4,5-dihydro-1H-pyrazole derivative or its pharmaceutically acceptable salt effectively increases the LXR transcriptional activity, and therefore can be usefully applied for preventing or treating a dysfunction in cholesterol metabolism, such as cholesterol gallstone, hyperlipidemia, or coronary atherosclerosis.
    Type: Application
    Filed: October 23, 2013
    Publication date: October 15, 2015
    Applicant: YUHAN CORPORATION
    Inventors: Chan-Sun Park, Young-Hwan Kim, Gyu-Jin Lee, Youn Hur, Eun-Hye Jung, Hee-Jae Tak, Seung-Yub Shin, Ho-Jin Lee, Chun-Ho Lee, Koo-Yeon Lee